

In vitro anticoagulant effects of Bungarus venoms on human plasma which are effectively neutralized by the PLA2-inhibitor varespladib

Article

Published Version

Creative Commons: Attribution 4.0 (CC-BY)

Open Access

Chowdhury, A., Fry, B. G., Samuel, S. P., Bhalla, A., Vaiyapuri, S. ORCID: <https://orcid.org/0000-0002-6006-6517>, Bhargava, P., Carter, R. W. and Lewin, M. R. (2024) In vitro anticoagulant effects of Bungarus venoms on human plasma which are effectively neutralized by the PLA2-inhibitor varespladib. *Toxicon*, 252. 108178. ISSN 0041-0101 Available at <https://centaur.reading.ac.uk/119443/>

It is advisable to refer to the publisher's version if you intend to cite from the work. See [Guidance on citing](#).

Publisher: Elsevier

All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the [End User Agreement](#).

www.reading.ac.uk/centaur

CentAUR

Central Archive at the University of Reading

Reading's research outputs online



In vitro anticoagulant effects of *Bungarus* venoms on human plasma which are effectively neutralized by the PLA₂-inhibitor varespladib

Abhinandan Chowdhury^{a,b}, Bryan G. Fry^{a,*}, Stephen P. Samuel^{c,d}, Ashish Bhalla^e, Sakthivel Vaiyapuri^f, Parul Bhargava^g, Rebecca W. Carter^d, Matthew R. Lewin^{c,d,**}

^a Adaptive Biotoxicology Lab, School of the Environment, University of Queensland, St Lucia, QLD, 4072, Australia

^b Department of Biochemistry & Microbiology, North South University, Dhaka, Bangladesh

^c Ophirex, Inc., Corte Madera, CA, 94925, USA

^d California Academy of Sciences, San Francisco, CA, 94118, USA

^e Post Graduate Institute of Medical Education and Research, Chandigarh, India

^f School of Pharmacy, University of Reading, Reading, RG6 6UB, UK

^g Department of Pathology and Laboratory Medicine, University of San Francisco, California, USA

ARTICLE INFO

Handling editor: Denise Tambourg

Keywords:

Bungarus

Plasma

Anticoagulation

Phospholipase A₂

Varespladib

Venom

ABSTRACT

Bungarus (krait) envenomings are well-known for their life-threatening neurotoxic effects. However, their impact on coagulation remains largely unexplored experimentally or clinically. This study, examined the effect of begins to examine venoms from four *Bungarus* species—*B. caeruleus*, *B. candidus*, *B. fasciatus*, and *B. flaviceps* on human platelet poor plasma coagulation parameters using thromboelastography and coagulation inhibition assays. *B. flaviceps* completely inhibited clotting, while *B. caeruleus* only delayed clot formation. In contrast, *B. candidus* and *B. fasciatus* did not affect clotting. Subsequent examinations into the anticoagulant biochemical mechanisms demonstrated divergent pathophysiological pathways. *B. caeruleus* venom anticoagulant effects were prevented by the addition of an excess of phospholipids, with anticoagulation thereby the result of phospholipid depletion. In contrast *B. flaviceps* anticoagulation was not affected by the addition of an excess of phospholipids. Further investigations demonstrated that *B. flaviceps* mediates its anticoagulant toxicity through the inactivation of coagulation enzymes. The anticoagulant effects of both *B. flaviceps* and *B. caeruleus* were nullified by varespladib, a phospholipase A₂ (PLA₂) inhibitor, revealing the toxin class involved. These results uncover previously unrecognized and unexplored anticoagulant effects of *Bungarus* venoms.

1. Introduction

Snakes from the Elapidae and Viperidae families cause most of the fatal snakebite envenomings worldwide (Tednes and Slesinger, 2024). While elapid snakes have neurotoxicity as a basal trait, certain derived lineages may potentially affect blood coagulation. The venoms Australian elapid snakes are unique in being primarily procoagulant through the use of Factor Xa and FVa recruited as toxins, with envenomings causing stroke in prey while producing consumptive coagulopathy in human bite victims (Zdenek et al., 2019a, 2019b; Lister et al., 2017; Sutherland and Tibballs, 2001). This is accomplished through the activation of Factor VII and, in some derived lineages, the additional activation of prothrombin (Chandrasekara et al., 2024). Other elapid venoms act in an

anticoagulant manner. For example, metalloprotease enzymes in *Naja* venoms deplete fibrinogen levels through the destructive cleavage of α and β chains (Bittenbinder et al., 2019). Snake venom phospholipase A₂ (PLA₂) toxins exert myriad effects, including depletion of phospholipid levels (such as *Micrurus* and *Pseudechis* venoms), and inhibition of clotting enzymes (such as inhibition of Factor Xa and thrombin by *Naja* venoms) (Zdenek et al., 2020; Youngman et al., 2019; Chowdhury et al., 2021, 2022a; Dashevsky et al., 2021; Bittenbinder et al., 2018; Kini, 2003; Kerns et al., 1999; Sunagar et al., 2015).

The genus *Bungarus* are elapid snakes that evolved between 25 and 30 million years ago (Biakzuala et al., 2023). Commonly referred to as “Kraits,” these consist of 12 *Bungarus* species, widespread across Southeast Asia. Their venoms are well-known to cause potent, flaccid paralysis with death due to respiratory failure when untreated

* Corresponding author.

** Corresponding author. Ophirex, Inc., Corte Madera, CA, 94925, USA.

E-mail addresses: bgfry@uq.edu.au (B.G. Fry), matt@ophirex.com (M.R. Lewin).

<https://doi.org/10.1016/j.toxicon.2024.108178>

Received 9 September 2024; Received in revised form 31 October 2024; Accepted 12 November 2024

Available online 13 November 2024

0041-0101/© 2024 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Acronyms

MA	The amplitude of detectable clot
MRTG	The maximum rate of thrombus generation
PLA ₂	Phospholipase A ₂
PPL	Phospholipid
R	The time to initial clot formation where formation is 2 mm
SP	Split point (SP), the time taken until the fibrin clot begins to form
TGG	The total thrombus generation
TMRTG	the time to maximum rate of thrombus generation
Va	Varespladib

(Slowinski, 1994). Signs and symptoms of krait bites encompass ptosis, ophthalmoplegia with progressive blurring of vision, ataxia and life-threatening bulbar palsies represented by dysphonia, dysphagia and neck weakness. Headache, increased oral secretions, abdominal pain, vomiting, intercostal and diaphragmatic failure (Deshwal and Gupta, 2015; Law et al., 2014; Trinh et al., 2010; Mao et al., 2017; Kularatne, 2002; Wang et al., 2021; Faiz et al., 2010). Bites often occur at night and may be asymptomatic as many as 10 or more hours following a bite (Suraweera et al., 2020). *Bungarus* venoms contain both pre- and post-synaptically acting toxins that can disrupt neurotransmission. Presynaptically the β -bungarotoxin heterodimeric complexes composed of by a kunitz peptide covalently linked to a PLA₂ toxin can also blocks voltage-gated potassium channels to impede the release of acetylcholine (Sunagar et al., 2015; Xie et al., 2021). Postsynaptically, three finger toxins (3FTx)- α -bungarotoxins antagonistically bind to the alpha-1 subunit of the nicotinic acetylcholine receptor, preventing acetylcholine from binding and triggering muscular contraction (Fry et al., 2003). While neurotoxicity is the dominant feature clinically, anticoagulant toxins have been isolated from *Bungarus* venom (Chen et al., 2014; Utkin et al., 2015). However the genus has not been systematically investigated and the venom concentrations tested have been clinically implausible, e.g. 10 mg/mL (Utkin et al., 2015).

In light of the literature and clinical observations in patients (SPS, MRL, unpublished) we sought to begin filling this knowledge gap

without clinical prejudice about its significance and investigate the coagulotoxic effects of four *Bungarus* venoms (*Bungarus caeruleus*, *B. candidus*, *B. fasciatus*, and *B. flaviceps*) spanning the geographic range and taxonomic diversity of this medically important genus (Fig. 1). Varespladib, a potent PLA₂ inhibitor varespladib was used to examine sPLA₂-dependent effects of these venoms and their inhibition even as its primary use in krait-bite envenoming would be most likely for neurotoxicity, its prevention if given early and antivenom resistant treatment failure (Ghose and Faiz, 2015; Gutiérrez et al., 2020; Ranawaka et al., 2013; Prasarnpun et al., 2005; Lewin et al., 2022; Gerardo et al., 2024).

2. Materials and methods

2.1. Venoms

Venom was sourced from licensed biological supply company MToxins, received under University of Queensland, Animal Ethics Approval March 15, 2021/AE000075, and work undertaken under UQ Biosafety Committee Approval #IBC/134B/SBS/2015. *Bungarus caeruleus*, *B. candidus*, *B. flaviceps*, *B. fasciatus* and *Naja nigricolis* (positive control) were reconstituted to 1 mg/ml concentrated venom stock by adding 50% glycerol and deionized water from lyophilized venom. The liquid stock was stored at -20°C for further use after confirming the concentration by using Thermo Fisher Scientific™ NanoDrop 2000 UV–Vis Spectrophotometer (ThermoFisher, Sydney, Australia).

2.2. Plasma and fibrinogen

Human-plasma work was performed under University of Queensland Biosafety Approval #IBC134BSBS2015 and Human Ethics Approval #2016000256. Australian Red Cross (44 Musk Street, Kelvin Grove, QLD 4059, Australia) supplied human platelet-poor plasma (3.2% citrated) under research approval #16- 04QLD-10. The plasma was aliquoted to 1.2 ml quantities after thawing and then flash-frozen in liquid nitrogen, stored at -80°C until required for testing. Frozen aliquots were thawed at 37°C in a Thermo Haake ARCTIC water bath during experiments. Fibrinogen was prepared to a concentration of 4 mg/ml by adding in Owen Koller (OK) buffer (Stago catalogue #00360) to 100 mg of fibrinogen (Lot#SLBZ2294 Sigma Aldrich, St. Louis, Missouri, United States), then aliquoted to 1 ml quantities, flash-frozen in




Fig. 1. Phylogenetic tree with the species studied in green with their corresponding distribution maps shown. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

liquid nitrogen, and stored at -80°C until further use.

2.3. Enzyme inhibitor

Small molecule PLA_2 inhibitor varespladib-HCl (LY315920) was provided by Ophirex, Inc., (Corte Madera, CA, 94925, USA and manufactured by ChemieTek, Inc. Indianapolis, Indiana Lot 001). The inhibitors arrived in powdered form and were first dissolved in 10% dimethyl sulfoxide (DMSO) and further diluted using deionized water to form 10 mM concentration main stocks. The final concentration of varespladib used in reactions was 0.56 mM.

2.4. Thromboelastography assays

To investigate the action of venom on human plasma, TEG5000 haemostasis analyzers (Haemonetics®, [Haemonetics.com](https://www.haemonetics.com), catalogue #07033) was used to carry out thromboelastography. Automated measurement was done after consecutive addition of 72 μl of 0.025M CaCl_2 (Stago catalogue #00367), 72 μl phospholipid (Stago catalogue #00597), 20 μl of the OK buffer (Stago catalogue #00360), 7 μl of 1 mg/ml of venom, and 189 μl human plasma into the reaction cup. For negative control, venom was replaced by 7 μl 50% deionized water/glycerol. *Naja nigricollis* was used as a positive control due to its reliably potent anticoagulant action (Bittenbinder et al., 2018; Kini, 2003; Kerns et al., 1999). To test the inhibitor efficacy of varespladib, 10 mM was added to the reaction cup instead of the OK buffer (to achieve a final concentration of 0.56 mM in reaction mixture). To evaluate phospholipid dependence, two concentrations of phospholipid were tested; 100% phospholipid was made as per manufacturer instructions of adding 5 ml OK buffer to phospholipid vial, and separately a 500% concentration of phospholipid was prepared by adding 1 ml OK buffer rather than 5 ml to the phospholipid powder. Each reaction was run for 30 min. To ascertain direct effects upon fibrinogen, the assays were repeated using purified fibrinogen (Sigma) at a reaction concentration of 4 mg/mL in place of plasma. Tests for fibrinogen destruction was also carried out for *B. flaviceps* by adding thrombin (7 μl Stago catalogue #00673) after carrying out the normal test on fibrinogen for 30 min 7 of Liquid Fib was added to check if clots were formed (Dobson et al., 2019; Debono et al., 2019).

2.5. Enzyme inactivation assays

To understand further the mechanism of *B. flaviceps*, enzyme activation tests were performed using previously published protocols (Zdenek et al., 2019b) on the coagulation analyser STA-R Max® (Stago, Asnières sur Seine, France). 1 mg/ml venom stock was diluted with OK buffer to prepare a 100 $\mu\text{g}/\text{ml}$ venom working stock. 25 μl of the working stock was loaded into cuvette automatically by the analyser (final concentration of venom in reaction mixture was 20 $\mu\text{g}/\text{ml}$) and other

reagents were added automatically according to the test requirements and procedure as per table below Table 1. 50% glycerol/deionized water was used instead of venom, in the negative control for plasma studies. The mean values for venom-only and venom-plus-factor conditions were calculated. % increase relative to the control was determined using the formula:

$$\frac{((\text{enzyme incubated with venom})/\text{enzyme-only}) - 1}{1} \times 100$$
 A value of 0 indicated no neutralization (no alteration in clotting time), while values > 0 indicated enzyme-inhibition, with values as % of enzyme-only control results.

2.6. Statistical analyses

All assays were run in triplicate. GraphPad PRISM 10.0.0 (GraphPad Prism Inc., La Jolla, CA, USA) was utilized for data visualization and statistical analyses.

3. Results

To determine the impact of *Bungarus* venoms on plasma clotting, they were first analyzed by thromboelastography under normal conditions and various clotting parameters were analyzed (Figs. 2A and 3). As expected, the positive control (*Naja nigricollis* venom) prevented clot formation throughout the maximum time limit of 1800 s. The effects of *Bungarus* venoms on plasma clotting were highly variable. *B. candidus* venom did not significantly affect any of the clotting parameters including: split point (SP), the time taken until the fibrin clot begins to form; R, the time to initial clot formation where formation is 2 mm; MA, the amplitude of detectable clot; MRTG, the maximum rate of thrombus generation; TGG, the total thrombus generation; or TMRTG, the time to maximum rate of thrombus generation. *B. fasciatus* also did not have significant effects upon clotting parameters. In contrast, *B. caeruleus* venom displayed moderate anticoagulant effect by impeding the time to clot formation extending SP, R, and TMRTG by $\sim 100\%$ relative to the spontaneous clotting control \geq with low-level effects upon MA, MRTG, and TGG. These patterns are consistent with impedance of the clotting cascade. *B. flaviceps* however was potentially anticoagulant, completely prevented clot formation, with all parameters (SP, R, TMRTG, MA, MRTG, and TGG) dramatically affected. This is indicative of a strong impact upon the clotting cascade.

Further tests were conducted to ascertain where in the clotting cascade *B. caeruleus* and *B. flaviceps* venoms were acting to produce their respective anticoagulant effects. We first evaluated the phospholipid dependency of the venom (Figs. 2B and 4). To test whether the mode of anticoagulation was due to phospholipid destruction, we increased the phospholipid (PPL) concentration by five-fold (500%) in the test. The excess of phospholipid restored normal clotting parameters for *B. caeruleus* venom, revealing that this species' venom mediates its anticoagulant action through the depletion of phospholipids, which are essential cofactors for endogenous clotting enzymes. However, the *B. flaviceps* anticoagulant effect was not impacted by the increased phospholipid levels, indicating that the underlying biochemical mechanisms lay elsewhere. Subsequent tests revealed *B. flaviceps* inhibited multiple clotting enzymes (Fig. 5). The extrinsic pathway enzyme FVIIa

Table 1
Inhibition assay protocols.

Assay	Procedure
Enzyme inhibition assays	Step 1: 25 μl venom +50 μl 0.025 M calcium +25 μl OK buffer +50 μl PPL +25 μl of enzyme [quantities used to replicate physiological conditions present in plasma were: 1.5 $\mu\text{g}/\text{ml}$ FVIIa Prolytix #HCVIIA-0031; 15 $\mu\text{g}/\text{ml}$ FIXa Prolytix #HCIXA-0050; 15 $\mu\text{g}/\text{ml}$ FXIa Prolytix #HCXIA-0160; or FXa Stago #00311; or thrombin Stago #00611]. Step 2: 120 s incubation at 37°C Step 3: Addition of 75 μl human plasma
Prothrombinase complex inhibition assay	Step 1: 25 μl venom +50 μl 0.025 M calcium +25 μl OK buffer +50 μl PPL +75 μl human plasma Step 2: 120 s incubation at 37°C Step 3: Addition of 25 μl Factor Xa (Stago #00311)







Table 2
Welch and Brown-Forsythe ANOVA tests of clotting factor inhibition from Fig. 5.

	FVIIa	FIXa	FXa	FXIa	P.C.	Thrombin
FVIIa		0.0174	0.0008	0.0012	0.3785	<0.0001
FIXa	0.0174		0.0109	0.6779	0.2278	0.0042
FXa	0.0008	0.0109		0.0025	0.1022	0.0518
FXIa	0.0012	0.6779	0.0025		0.2186	0.0003
P.C.	0.3785	0.2278	0.1022	0.2186		0.128
Thrombin	<0.0001	0.0042	0.0518	0.0003	0.128	



P.C. = Prothrombinase Complex.
p-values are Welch and Brown-Forsythe ANOVA.

A) Venom Only

Human plasma (negative control)

*N. nigricolis* (positive control)*B. caeruleus**B. candidus**B. fasciatus**B. flaviceps*

B) Venom + Excess Phospholipid

B. caeruleus (500% PPL)*B. flaviceps* (500% PPL)

C) Venom + Varespladib



B. caeruleus (Va)*B. flaviceps* (Va)

Fig. 2. Overlaid thromboelastography traces showing effects of venoms on platelet-poor plasma. Blue traces = spontaneous clot controls, red traces = plasma treated with venom, phospholipid (PPL), or varespladib (Va). SP = split point, time taken until clot begins to form (min). R = time to initial clot formation where the fibrin clot is 2 mm (min). MA = amplitude of detectable clot (mm). MRTG = maximum rate of thrombus generation (dynes/cm²/s). TMRTG = time to maximum rate of thrombus generation (min). TGG = total thrombus generation (dynes/cm²). Values are N = 3 mean ± standard deviation. R = 1800 indicates that *N. nigricolis* and *B. flaviceps* venom both prevented clotting within the machine maximum measurement time of 1800 s. Further tests of the two anticoagulant *Bungarus* venoms to determine if the venom effect was due to B) degradation of phospholipids and C) if the anticoagulant mechanism (whether due to phospholipid degradation or otherwise) was mediated by PLA₂ toxins and could be blocked by the phospholipase A₂ specific inhibitor varespladib (Va). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

clotting time was increased by 103.56 ± 2.65% increase in clotting time. The intrinsic pathway enzymes were also affected: FIXa clotting time increased by 76.11 ± 0.49% increase, and FXIa clotting time increased by 73.49 ± 2.10%. The common pathway was also affected, with FXa clotting time increased by 17.88 ± 4.48%, prothrombinase complex clotting time increased by 178.66 ± 38.97%; and thrombin clotting time increased by 36.96 ± 1.82% in (Fig. 5). The prothrombinase complex is made up of by FXa and FVa, with phospholipid an essential cofactor for its activity. As the impact upon the prothrombinase complex effect by *B. flaviceps* venom was much stronger than that upon FXa, and phospholipid degradation was not a feature for this venom, this leaves binding to FVa as the mechanism of inhibition for the effect upon prothrombinase complex and therefore a major site of action. The cumulative effect of acting upon multiple enzymatic processes results observed for this venom might be having a particularly strong net anticoagulant effect.

Subsequent tests were undertaken to ascertain whether the anticoagulant activities of *B. caeruleus* and *B. flaviceps* were driven by PLA₂-toxins. This was accomplished through the use of the PLA₂-specific small-molecule enzyme-inhibitor varespladib. Despite their divergent effects, varespladib was effective in reversing the anticoagulant activity induced by both *B. caeruleus* and *B. flaviceps*. In both case, there was a restoration of thromboelastography clotting parameters to levels (Figs. 2C and 6), thereby revealing that the anticoagulant actions of these venoms are mediated by PLA₂ toxins. As illustrated by the site of action studies, the PLA₂ toxins may be exerting their observed anticoagulant effects in radically different ways. In this experimental system, the *B. caeruleus* anticoagulation is due to enzymatic degradation of phospholipids. In contrast, the *B. flaviceps* anticoagulation appears to be due to non-enzymatic actions by the PLA₂ toxins, with them instead acting as enzyme inhibitors.




Fig. 3. Thromboelastography traces depicted as histograms showing effects of venoms (only) on plasma. A) SP = split point, time taken until clot begins to form (min). B) R = time to initial clot formation where fibrin clot is 2 mm (min). C) MA = amplitude of detectable clot (mm). D) MRTG = maximum rate of thrombus generation. E) TMRTG = time to maximum rate of thrombus generation. F) TGG = total thrombus generation. Spontaneous plasma = clotting time without venom. Note for A) and B) *N. nigricollis* and *B. flaviceps* venom both prevented clotting within the machine maximum measurement time of 1800 s. Values are N = 3 mean \pm standard deviation. *p*-values are Welch and Brown-Forsythe ANOVA. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

4. Discussion

Human plasma *in vitro* data in this studied documented differential coagulotoxicity in the venoms of four *Bungarus* species (*B. caeruleus*, *B. candidus*, *B. fasciatus*, and *B. flaviceps*) of elapid snakes. In this *in vitro* *B. candidus* and *B. fasciatus* did not have any significant effects upon coagulation parameters, *B. caeruleus* had a moderate anticoagulant effect, while *B. flaviceps* venom displayed profound anticoagulant attributes, and isolated anticoagulant toxins present in the venom in only low concentrations (Chen et al., 2014). Our findings support this as *B. fasciatus* had negligible effects in this study, which tested venom at $< 1/500$ th the concentration than previous work using extremely high concentrations of venom (e.g. 10 mg/mL) (Utkin et al., 2015).

As a whole, krait venoms are rich in three-finger toxins, kunitz-type peptides, and PLA₂-scaffolds, all of which contribute to the stereotypical neurotoxicity of these bites (Xie et al., 2021; Alam et al., 2023; Ali et al., 2013). While all four venoms tested are known to contain abundant

PLA₂s, only *B. caeruleus* and *B. flaviceps* demonstrated strong anticoagulant effects *in vitro*. Normalization of coagulation by the addition of the PLA₂-inhibitor varespladib supports a role for venom PLA₂ toxins in mediating these effects in both venoms. This efficacy of varespladib was consistent with previous publications on the effectiveness of this inhibitor against other PLA₂-mediated venom actions (Zdenek et al., 2020; Chowdhury et al., 2021, 2022a; Dashevsky et al., 2021; Lewin et al., 2016a, 2016b, 2022; Youngman et al., 2020, 2022; Salvador et al., 2019; Bryan-Quirós et al., 2019). However, while the anticoagulant actions of *B. caeruleus* and *B. flaviceps* were dependent on venom PLA₂ toxins, the mechanisms of action appear distinct from each other. *B. caeruleus* created an anticoagulant state through phospholipid destruction, thereby depleting the levels of this essential cofactor used by endogenous clotting enzymes. By increasing the available phospholipid by 500%, normal clotting parameters were restored, an anticoagulant pattern previously observed for the elapid species *Micrurus laticollaris* (Dashevsky et al., 2021). In contrast, raising the phospholipid levels did




Fig. 4. Thromboelastography traces depicted as histograms showing effects of *B. caeruleus* venom on human plasma mixed with normal test concentration of phospholipid (100%) and a five-fold higher (500%) phospholipid concentration A) SP = split point, time taken until clot begins to form (min). B) R = time to initial clot formation where formation is 2 mm. C) MA = amplitude of detectable clot. D) MRTG = maximum rate of thrombus generation. E) TMRTG = time to maximum rate of thrombus generation. F) TGG = total thrombus generation. Spontaneous plasma = the clotting time without venom. PPL = Phospholipid. Values are N = 3 mean \pm standard deviation. *p*-values are Welch and Brown-Forsythe ANOVA. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

not negate the anticoagulant effects of *B. flaviceps*. Instead, this venom phenotype is apparently anticoagulant by toxins built upon PLA₂-scaffolds using non-enzymatic mechanisms to inhibit a myriad of clotting enzymes, with the rank order of FVIIa > FIXa = FXIa > thrombin > FXa. However, even more potentially affected was the formation of the prothrombinase complex, with the results suggesting this is due to binding to FVa to prevent it from forming a complex with FXa. Inhibiting clotting factors including the prothrombinase complex has been observed for other elapid snakes (Zdenek et al., 2020; Bittenbinder et al., 2018).

In recent years, several investigators have examined the effects of direct toxin inhibitors (DTIs) such as varespladib for the purpose of early intervention and reversal of toxic PLA₂ effects (Gerardo et al., 2024; Bulfone et al., 2018; Williams et al., 2019). These therapeutics are being intensively investigated as potential treatment options for venom sPLA₂-induced toxicity and may be suitable for field treatments alone or in combination with other similarly orally bioavailable toxin inhibitors (Lewin et al., 2016a; Bulfone et al., 2018; Puzari et al., 2021; Albulescu

et al., 2020). As the bites from such venomous species occur more in rural or remote areas where fast medical interventions are required but mostly delayed, the importance of these inhibitors as first-aid interventions cannot be overstated. With respect to *Bungarus* venoms that typically have substantial proportions of PLA₂s, varespladib has been of particular interest to prevent, abrogate or reverse neurotoxicity (Gutiérrez et al., 2020; Puzari et al., 2021; Oh et al., 2017; Patra et al., 2019; Chapeaurouge et al., 2018; Hia et al., 2020). DTIs such as prinomastat, marimastat and varespladib have shown promising effect in curbing the coagulotoxicity of snake. The results of this study further suggest the utility of varespladib in negating certain coagulotoxic effects (Bittenbinder et al., 2019; Zdenek et al., 2020; Chowdhury et al., 2021, 2022a; Dashevsky et al., 2021; Lewin et al., 2016a, 2016b, 2022; Youngman et al., 2020, 2022; Salvador et al., 2019; Bryan-Quirós et al., 2019; Murphy et al., 2024; Howes et al., 2007; Bourke et al., 2020; Jones et al., 2022). In addition to the previously demonstrated experimental utility for reversing the effects of presynaptic neurotoxins, but do not in




Fig. 5. Relative inhibition of specific points upon the clotting cascade by *B. flaviceps* venom. A value of 0 indicates no alteration in clotting time relative to control, and hence no inactivation of the pathway being assessed. Values are $N = 3 \pm$ standard deviation. Welch and Brown-Forsythe ANOVA tests p -values are shown in Table 2. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

any way imply that this is an important factor in the current clinical management of krait bite envenoming (Gutiérrez et al., 2020; Murphy et al., 2024).

Several limitations of the study are worthy of note: Only four *Bungarus* species were included, and all four species occupy large ranges, future work should investigate intra-species variations to ascertain regional, ontological and treatment efficacy variations (Alirol et al., 2015). In addition, the full range of *Bungarus* species should be investigated to ascertain their relative coagulotoxicity, especially in light of the extreme variation in relative potency and sites of action observed in this study. In addition, future work through *in vivo* studies is required to confirm the *in vitro* effects observed in this study and platelet rich plasma, whole blood or more complete hematological preparations should be considered for investigation.

Reports on human envenomings by *Bungarus* species generally focus on stereotypical neurotoxic effects, duration of recovery, antivenom as well as other treatment resistance and unusual CNS manifestations. However, changes in blood coagulation parameters are not routinely measured in clinical cases (Law et al., 2014; Trinh et al., 2010; Mao et al., 2017; Kularatne, 2002; Oh et al., 2017; Silva et al., 2016; Tongpoo et al., 2018; Chaisakul et al., 2017). Given the paucity of documented coagulopathy in relation to *B. caeruleus* and particularly that of *B. flaviceps* venoms, our study highlights the rare, but potential significance of this aspect where patients might already be vulnerable from other causes such as malnutrition, alcoholic liver disease, or chronic parasitic diseases that impact hepatic function (Boyer et al., 2015). This study does not consider or opine the contexts in which coagulation testing might be routinely done or beneficial in these bites, but rather highlights the potential and aims to raise awareness that there are unanswered questions and unrecognized phenomena relating to many envenoming syndromes. By analogy, an example of observational bias in

the field of snakebite envenoming research has been highlighted in recent review of neurotoxic effects of viperid snakebite where hemotoxic envenoming is the most prominently observed and taught feature. Yet, many who treat Russell's viper bites in southern India will have encountered severe neurotoxicity in patients which also have life-threatening venom-induced consumption coagulopathy (Chowdhury et al., 2022b; Lay et al., 2023; Lay and Hodgson, 2024). Our study's notable findings relate to the strong anticoagulant effect of *B. flaviceps* on human plasma and the raising of questions and awareness for new avenues of basic and clinical research. Finally, these findings contribute to a holistic understanding of venom diversity.

Ethical statement

Hereby, I, Abhinandan Chowdhury consciously assure that for the "In vitro examination of anticoagulant effects of *Bungarus* (krait) venoms on human plasma." the following is fulfilled:

- 1) This material is the authors' own original work, which has not been previously published elsewhere.
- 2) The paper is not currently being considered for publication elsewhere.
- 3) The paper reflects the authors' own research and analysis in a truthful and complete manner.
- 4) The paper properly credits the meaningful contributions of co-authors and co-researchers.
- 5) The results are appropriately placed in the context of prior and existing research.
- 6) All sources used are properly disclosed (correct citation). Literally copying of text must be indicated as such by using quotation marks and giving proper reference.
- 7) All authors have been personally and actively involved in substantial work leading to the paper, and will take public responsibility for its content.

The violation of the Ethical Statement rules may result in severe consequences.

To verify originality, your article may be checked by the originality detection software iThenticate. See also <http://www.elsevier.com/editors/plagdetect>.

Funding source

Ophirex, Inc., Corte Madera, CA 94925, USA.

CRediT authorship contribution statement

Abhinandan Chowdhury: Writing – original draft, Methodology, Investigation, Formal analysis, Data curation. **Bryan G. Fry:** Writing – review & editing, Supervision, Project administration, Methodology, Investigation, Conceptualization. **Stephen P. Samuel:** Writing – review & editing, Validation, Formal analysis. **Ashish Bhalla:** Writing – review & editing, Formal analysis. **Sakthivel Vaiyapuri:** Writing – review & editing, Formal analysis. **Parul Bhargava:** Writing – review & editing, Formal analysis. **Rebecca W. Carter:** Writing – review & editing, Formal analysis. **Matthew R. Lewin:** Writing – review & editing, Visualization, Supervision, Resources, Formal analysis, Conceptualization.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.




Fig. 6. Histograms showing comparisons of thromboelastography parameters affected by the addition of 0.56 mM varespladib. A) SP = split point, time taken until clot begins to form. B) R = time to initial clot formation where formation is 2 mm. C) MA = amplitude of detectable clot. D) MRTG = maximum rate of thrombus generation. E) TMRTG = time to maximum rate of thrombus generation. F) TGG = total thrombus generation. Spontaneous plasma = clotting time without venom (negative control). Va = Varespladib. Values are N = 3 mean \pm standard deviation. p-values are Welch and Brown-Forsythe ANOVA. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

Data availability

Data will be made available on request.

References

- Alam, M.J., Maruf, M.M.H., Iqbal, M.A., Hasan, M., Sohan, M.S.R., Shariar, M.R., Haidar, I.K. Al, Chowdhury, M.A.W., Ghose, A., Hoque, K.M.F., et al., 2023. Evaluation of the properties of *Bungarus caeruleus* venom and checking the efficacy of antivenom used in Bangladesh for its bite treatment. *Toxicon X* 17. <https://doi.org/10.1016/J.TOXCX.2023.100149>.
- Albulescu, L., Xie, C., Ainsworth, S., Alsolaiss, J., Crittenden, E., Dawson, C.A., Softley, R., Bartlett, K.E., Harrison, R.A., Kool, J., et al., 2020. A therapeutic combination of two small molecule toxin inhibitors provides broad preclinical efficacy against viper snakebite. *Nat. Commun.* 11, 1–14. <https://doi.org/10.1038/s41467-020-19981-6>.
- Ali, S.A., Yang, D.C., Jackson, T.N.W., Undheim, E.A.B., Koludarov, I., Wood, K., Jones, A., Hodgson, W.C., McCarthy, S., Ruder, T., et al., 2013. Venom proteomic characterization and relative antivenom neutralization of two medically important Pakistani elapid snakes (*Bungarus sindanus* and *Naja Naja*). *J. Proteomics* 89, 15–23. <https://doi.org/10.1016/J.JPROT.2013.05.015>.
- Alirol, E., Lechevalier, P., Zamatto, F., Chappuis, F., Alcoba, G., Potet, J., 2015. Antivenoms for snakebite envenoming: what is in the research pipeline? *PLoS Neglected Trop. Dis.* 9, 1–11. <https://doi.org/10.1371/journal.pntd.0003896>.
- Biakzuala, L., Lalremsanga, H.T., Santra, V., Dhara, A., Ahmed, M.T., Mallick, Z.B., Kuttalam, S., Amarasinghe, A.A.T., Malhotra, A., 2023. Molecular phylogeny reveals distinct evolutionary lineages of the banded krait, *Bungarus fasciatus* (Squamata, Elapidae) in Asia. *Sci. Rep.* 13, 1–14. <https://doi.org/10.1038/s41598-023-28241-8>.
- Bittenbinder, M.A., Zdenek, C.N., op den Brouw, B., Youngman, N.J., Dobson, J.S., Naude, A., Vonk, F.J., Fry, B.G., 2018. Coagulotoxic cobras: clinical implications of strong anticoagulant actions of African spitting *Naja* venoms that are not neutralised by antivenom but are by LY315920 (varespladib). *Toxins (Basel)* 10, 516. <https://doi.org/10.3390/toxins10120516>.
- Bittenbinder, M.A., Dobson, J.S., Zdenek, C.N., op den Brouw, B., Naude, A., Vonk, F.J., Fry, B.G., 2019. Differential destructive (Non-Clotting) fibrinolytic activity in Afro-Asian elapid snake venoms and the links to defensive hooding behavior. *Toxicol. Vitro* 60, 330–335. <https://doi.org/10.1016/j.tiv.2019.05.026>.
- Bourke, L.A., Youngman, N.J., Zdenek, C.N., Op Den Brouw, B., Violette, A., Fourmy, R., Fry, B.G., 2020. *Trimeresurus albolabris* snakebite treatment implications arising from ontogenetic venom comparisons of anticoagulant function, and antivenom efficacy. *Toxicol. Lett.* 327, 2–8. <https://doi.org/10.1016/j.toxlet.2020.03.009>.
- Boyer, L., Alagón, B.G.B.G., Fry, T.N.W., Jackson, K.K.S., Signs, J.P.C., 2015. Symptoms and treatment of envenomation. In: Fry, B.G. (Ed.), *Venomous Reptiles and Their Toxins: Evolution, Pathophysiology and Biodiscovery*. Oxford University Press, New York, pp. 32–60.
- Bryan-Quirós, W., Fernández, J., Gutiérrez, J.M., Lewin, M.R., Lomonte, B., 2019. Neutralizing properties of LY315920 toward snake venom group I and II myotoxic phospholipases A2. *Toxicon* 157, 1–7. <https://doi.org/10.1016/j.toxicon.2018.11.292>.
- Bulfone, T.C., Samuel, S.P., Bickler, P.E., Lewin, M.R., 2018. Developing small molecule therapeutics for the initial and adjunctive treatment of snakebite. *J. Trop. Med.* 2018, 1–10. <https://doi.org/10.1155/2018/4320175>.
- Chaisakul, J., Ahmad Rusmili, M.R., Hodgson, W.C., Hattachote, P., Suwan, K., Inchan, A., Chanhom, L., Othman, I., Chootip, K., 2017. A pharmacological examination of the cardiovascular effects of Malayan krait (*Bungarus candidus*) venoms. *Toxins* 9, 122. <https://doi.org/10.3390/TOXINS9040122>, 2017, 9, 122.
- Chandrasekara, U., Chowdhury, A., Seneci, L., Zdenek, C.N., Dunstan, N., Fry, B.G., 2024. From venom to vein: factor VII activation as a major pathophysiological target

- for procoagulant Australian elapid snake venoms. *Toxins* 16, 430. <https://doi.org/10.3390/TOXINS16100430>. Page 430 2024, 16.
- Chapeaurouge, A., Silva, A., Carvalho, P., McCleary, R.J.R., Modahl, C.M., Perales, J., Kini, R.M., Mackessy, S.P., 2018. Proteomic deep mining the venom of the red-headed krait, *Bungarus flaviceps*. *Toxins* 10, 373. <https://doi.org/10.3390/TOXINS10090373>. Page 373 2018, 10.
- Chen, W., Goh, L.C., Kang, T.S., Manjunatha Kini, R., 2014. Identification and characterisation of novel inhibitors on extrinsic tenase complex from *Bungarus fasciatus* (banded krait) venom. *Thromb. Haemostasis* 112, 700–715. <https://doi.org/10.1160/TH13-12-1063>.
- Chowdhury, A., Lewin, M.R., Zdenek, C.N., Carter, R.W., Fry, B.G., Youngman, N.J., Liu, J., Lewin, M.R., Carter, R.W., Fry, B.G., 2021. The relative efficacy of chemically diverse small-molecule enzyme-inhibitors against anticoagulant activities of African spitting cobra (*Naja* species) venoms. *Front. Immunol.* 12, 1–9. <https://doi.org/10.3389/FIMMU.2021.752442>.
- Chowdhury, A., Youngman, N.J., Liu, J., Lewin, M.R., Carter, R.W., Fry, B.G., 2022a. The relative efficacy of chemically diverse small-molecule enzyme-inhibitors against anticoagulant activities of black snake (*Pseudechis* spp.) venoms. *Toxicol. Lett.* 366, 26–32. <https://doi.org/10.1016/J.TOXLET.2022.06.009>.
- Chowdhury, A., Zdenek, C.N., Fry, B.G., 2022b. Diverse and dynamic alpha-neurotoxicity within venoms from the palaearctic viperid snake clade of *Daboia*, *Macrovipera*, *Montivipera*, and *Vipera*. *Neurotox. Res.* 1, 1–9. <https://doi.org/10.1007/S12640-022-00572-W>.
- Dashevsky, D., Bénard-Valle, M., Neri-Castro, E., Youngman, N.J., Zdenek, C.N., Alagón, A., Portes-Junior, J.A., Frank, N., Fry, B.G., 2021. Anticoagulant *Micrurus* venoms: targets and neutralization. *Toxicol. Lett.* 337, 91–97. <https://doi.org/10.1016/J.TOXLET.2020.11.010>.
- Debono, J., Bos, M.H.A., Do, M.S., Fry, B.G., 2019. Clinical implications of coagulotoxic variations in Mamushi (Viperidae: *Gloydius*) snake venoms. *Comp. Biochem. Physiol., Part C: Toxicol. Pharmacol.* 225, 1–11. <https://doi.org/10.1016/j.cbpc.2019.108567>.
- Deshwal, R., Gupta, V., 2015. Krait envenomation disguised as heat exhaustion in a wilderness setting. *Wilderness Environ. Med.* 26, 102–104. <https://doi.org/10.1016/j.wem.2014.08.005>.
- Dobson, J.S., Zdenek, C.N., Hay, C., Violette, A., Fourmy, R., Cochran, C., Fry, B.G., 2019. Varanid lizard venoms disrupt the clotting ability of human fibrinogen through destructive cleavage. *Toxins (Basel)* 11, 1–13. <https://doi.org/10.3390/toxins11050255>.
- Faiz, A., Ghose, A., Ahsan, M.F., Rahman, M.R., Amin, M.R., Mahtab, M., Hassan, U., Chowdhury, M.A.W., Kuch, U., Rocha, T., et al., 2010. The greater black krait (*Bungarus niger*), a newly recognized cause of neuro-myotoxic snake bite envenoming in Bangladesh. *J. Neurol.* 113, 3181–3193. <https://doi.org/10.1093/brain/awq265>.
- Fry, B.G., Wüster, W., Kini, R.M., Brusic, V., Khan, A., Venkataraman, D., Rooney, A.P., 2003. Molecular evolution and phylogeny of elapid snake venom three-finger toxins. *J. Mol. Evol.* 57, 110–129. <https://doi.org/10.1007/S00239-003-2461-2>.
- Gerardo, C.J., Carter, R.W., Kumar, S., Shirazi, F.M., Kotehal, S.D., Akpunonu, P.D., Bhalla, A., Schwartz, R.B., Bammigatti, C., Manikath, N., et al., 2024. Oral varespladib for the treatment of snakebite envenoming in India and the USA (BRAVO): a phase II randomised clinical trial. *BMJ Glob. Health* 9, 1–10. <https://doi.org/10.1136/bmjgh-2024-015985>.
- Ghose, A., Faiz, A., 2015. Snake envenomation in Bangladesh. In: *Toxinology: Clinical Toxicology in Asia Pacific and Africa*. Springer Netherlands, pp. 233–249. ISBN 9789400763869.
- Gutiérrez, J.M., Lewin, M.R., Williams, D.J., Lomonte, B., 2020. Varespladib (LY315920) and methyl varespladib (LY333013) abrogate or delay lethality induced by presynaptically acting neurotoxic snake venoms. *Toxins (Basel)* 12, 1–20. <https://doi.org/10.3390/toxins12020131>.
- Hia, Y.L., Tan, K.Y., Tan, C.H., 2020. Comparative venom proteomics of banded krait (*Bungarus fasciatus*) from five geographical locales: correlation of venom lethality, immunoreactivity and antivenom neutralization. *Acta Trop.* 207, 105460. <https://doi.org/10.1016/J.ACTATROPICA.2020.105460>.
- Howes, J.M., Theakston, R.D.G., Laing, G.D., 2007. Neutralization of the haemorrhagic activities of viperine snake venoms and venom metalloproteinases using synthetic peptide inhibitors and chelators. *Toxicon* 49, 734–739. <https://doi.org/10.1016/j.toxicon.2006.11.020>.
- Jones, L., Youngman, N.J., Neri-Castro, E., Guadarrama-Martínez, A., Lewin, M.R., Carter, R., Frank, N., Fry, B.G., 2022. Differential antivenom and small-molecule inhibition of novel coagulotoxic variations in *Atropoides*, *Cerrhopidion*, *Metapilcoatus*, and *Porthidium* viperid snake venoms. *Toxins (Basel)* 14, 511. <https://doi.org/10.3390/TOXINS14080511>.
- Kerns, R.T., Kini, R.M., Stefansson, S., Evans, H.J., 1999. Targeting of venom phospholipases: the strongly anticoagulant phospholipase A2 from *Naja nigricollis* venom binds to coagulation factor Xa to inhibit the prothrombinase complex. *Arch. Biochem. Biophys.* 369, 107–113. <https://doi.org/10.1006/abbi.1999.1345>.
- Kini, R.M., 2003. Excitement ahead: structure, function and mechanism of snake venom phospholipase A2 enzymes. *Toxicon* 42, 827–840. <https://doi.org/10.1016/j.toxicon.2003.11.002>.
- Kularatne, S.A.M., 2002. Common krait (*Bungarus caeruleus*) bite in Anuradhapura, Sri Lanka: a prospective clinical study, 1996–98. *Postgrad. Med. J.* 78, 276–280. <https://doi.org/10.1136/PMJ.78.919.276>.
- Law, A.D., Agrawal, A.K., Bhalla, A., 2014. Indian common krait envenomation presenting as coma and hypertension: a case report and literature review. *J. Emergencies, Trauma, Shock* 7, 126–128. <https://doi.org/10.4103/0974-2700.130887>.
- Lay, M., Hodgson, W.C., 2024. Isolation and pharmacological characterisation of pre-synaptic neurotoxins from Thai and Javanese Russell's viper (*Daboia siamensis*) venoms. *Toxins (Basel)* 15, 62. <https://doi.org/10.3390/TOXINS16090405>.
- Lay, M., Liang, Q., Isbister, G.K., Hodgson, W.C., 2023. *In vitro* efficacy of antivenom and varespladib in neutralising Chinese Russell's viper (*Daboia siamensis*) venom toxicity. *Toxins (Basel)* 15, 62. <https://doi.org/10.3390/TOXINS15010062>.
- Lewin, M.R., Samue, S.P., Merkel, J., Bickler, P., 2016a. Varespladib (LY315920) appears to be a very potent, broad-spectrum, inhibitor of snake venom PLA2s from six continents. *Toxicon* 117, 103–104. <https://doi.org/10.1016/J.TOXICON.2016.04.006>.
- Lewin, M., Samuel, S., Merkel, J., Bickler, P., 2016b. Varespladib (LY315920) appears to be a potent, broad-spectrum, inhibitor of snake venom phospholipase A2 and a possible pre-referral treatment for envenomation. *Toxins (Basel)* 8, 1–16. <https://doi.org/10.3390/toxins8090248>.
- Lewin, M.R., Carter, R.W., Matteo, I.A., Samuel, S.P., Rao, S., Fry, B.G., Bickler, P.E., 2022. Varespladib in the treatment of snakebite envenoming: development history and preclinical evidence supporting advancement to clinical trials in patients bitten by venomous snakes. *Toxins (Basel)* 14. <https://doi.org/10.3390/TOXINS14110783/S1>.
- Lister, C., Arbuckle, K., Jackson, T.N.W., Debono, J., Zdenek, C.N., Dashevsky, D., Dunstan, N., Allen, L., Hay, C., Bush, B., et al., 2017. Catch a tiger snake by its tail: differential toxicity, Co-factor dependence and antivenom efficacy in a procoagulant clade of Australian venomous snakes. *Comp. Biochem. Physiol., Part C: Toxicol. Pharmacol.* 202, 39–54. <https://doi.org/10.1016/j.cbpc.2017.07.005>.
- Mao, Y.C., Liu, P.Y., Chiang, L.C., Liao, S.C., Su, H.Y., Hsieh, S.Y., Yang, C.C., 2017. *Bungarus multicinctus* Multicinctus snakebite in Taiwan. *Am. J. Trop. Med. Hyg.* 96, 1497. <https://doi.org/10.4269/AJTMH.17-0005>.
- Murphy, K., Tasoulis, T., Dunstan, N., Isbister, G.K., 2024. Anticoagulant activity in Australasian elapid snake venoms and neutralisation with antivenom and varespladib. *Toxicon* 247, 107836. <https://doi.org/10.1016/J.TOXICON.2024.107836>.
- Oh, A.M.F., Tan, C.H., Ariarane, G.C., Quraishi, N., Tan, N.H., 2017. Venomics of *Bungarus caeruleus* (Indian krait): comparable venom profiles, variable immunoreactivities among specimens from Sri Lanka, India and Pakistan. *J. Proteomics* 164, 1–18. <https://doi.org/10.1016/J.JPROT.2017.04.018>.
- Patra, A., Chanda, A., Mukherjee, A.K., 2019. Quantitative proteomic analysis of venom from Southern India common krait (*Bungarus Caeruleus*) and identification of poorly immunogenic toxins by immune-profiling against commercial antivenom, 16, 457–469. <https://doi.org/10.1080/14789450.2019.1609945>.
- Prasarnpun, S., Walsh, J., Awad, S.S., Harris, J.B., 2005. Envenoming bites by kraits: the biological basis of treatment-resistant neuromuscular paralysis. *Brain* 128, 2987–2996. <https://doi.org/10.1093/BRAIN/AWH642>.
- Puzari, M.U., Fernandes, P.A., Mukherjee, A.K., 2021. Advances in the therapeutic application of small-molecule inhibitors and repurposed drugs against snakebite. *J. Med. Chem.* 64, 13938–13979. <https://doi.org/10.1021/acs.jmedchem.1c00266>.
- Ranawaka, U.K., Lalloo, D.G., de Silva, H.J., 2013. Neurotoxicity in snakebite—the limits of our knowledge. *PLoS Neglected Trop. Dis.* 7, e2302. <https://doi.org/10.1371/journal.pntd.0002302>.
- Salvador, G.H.M., Gomes, A.A.S., Bryan-Quirós, W., Fernández, J., Lewin, M.R., Gutiérrez, J.M., Lomonte, B., Fontes, R.M., 2019. Structural basis for phospholipase A2-like toxin inhibition by the synthetic compound varespladib (LY315920). *Sci. Rep.* 9, 1–13. <https://doi.org/10.1038/s41598-019-53755-5>.
- Silva, A., Maduwage, K., Sedgwick, M., Pilapitiya, S., Weerawansa, P., Dahanayaka, N.J., Buckley, N.A., Johnston, C., Siribaddana, S., Isbister, G.K., 2016. Neuromuscular effects of common krait (*Bungarus caeruleus*) envenoming in Sri Lanka. *PLoS Neglected Trop. Dis.* 10, e0004368. <https://doi.org/10.1371/JOURNAL.PNTD.0004368>.
- Slowinski, J.B., 1994. Phylogenetic analysis of *Bungarus* (Elapidae) based on morphological characters. *J. Herpetol.* 28, 440–446.
- Sunagar, K., Jackson, T., Reeks, T., Fry, B.G., 2015. Group I phospholipase A2 enzymes. In: *Venomous Reptiles and Their Toxins: Evolution, Pathophysiology and Biodiscovery*. Oxford University Press, New York, pp. 327–334.
- Suraweera, W., Warrell, D., Whitaker, R., Menon, G., Rodrigues, R., Fu, S.H., Begum, R., Sati, P., Piyasena, K., Bhatia, M., et al., 2020. Trends in snakebite deaths in India from 2000 to 2019 in a nationally representative mortality study. *Elife* 9, 1–37. <https://doi.org/10.7554/eLife.54076>.
- Sutherland, S.K., Tibballs, J., 2001. In: *Australian Animal Toxins: the Creatures, Their Toxins, and Care of the Poisoned Patient*, second ed. Oxford University Press. ISBN 019550643X.
- Tednes, M., Slesinger, T.L., 2024 Jan. Evaluation and Treatment of Snake Envenomations. 2024 [Updated 2024 Sep 10]. In: *StatPearls [Internet]*. Treasure Island (FL): StatPearls Publishing. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK53151/>.
- Tongpoo, A., Sriapha, C., Pradoo, A., Udomsubpayakul, U., Srisuma, S., Wananukul, W., Trakulsrichai, S., 2018. Krait envenomation in Thailand. *Therapeut. Clin. Risk Manag.* 14, 1711–1717. <https://doi.org/10.2147/TCRM.S169581>.
- Trinh, K.X., Khac, Q. Le, Trinh, L.X., Warrell, D.A., 2010. Hyponatraemia, rhabdomyolysis, alterations in blood pressure and persistent mydriasis in patients envenomed by Malayan kraits (*Bungarus candidus*) in southern Viet Nam. *Toxicon* 56, 1070–1075. <https://doi.org/10.1016/J.TOXICON.2010.06.026>.
- Utkin, Y.N., Gantsova, E.A., Andreeva, T.V., Starkov, V.G., Ziganshin, R.H., Anh, H.N., Thao, N.T.T., Khoa, N.C., Tsetlin, V.I., 2015. Venoms of kraits *Bungarus Multicinctus* and *Bungarus fasciatus* contain anticoagulant proteins. *Dokl. Biochem. Biophys.* 460, 53–58. <https://doi.org/10.1134/S1607672915010159/METRICS>.

- Wang, N., Wu, X., Zhang, S., Shen, W., Li, N., 2021. Local tissue necrosis and thrombocytopenia following *Bungarus multicinctus* envenomation in a child. Arch. Argent. Pediatr. 119, E80–E83. <https://doi.org/10.5546/AAP.2021.ENG.E80>.
- Williams, H.F., Layfield, H.J., Vallance, T., Patel, K., Bicknell, A.B., Trim, S.A., Vaiyapuri, S., 2019. The urgent need to develop novel strategies for the diagnosis and treatment of snakebites. Toxins (Basel). 11, 1–29.
- Xie, B., Dashevsky, D., Rokyta, D., Ghezellou, P., Fathinia, B., Shi, Q., Richardson, M.K., Fry, B.G., 2021. Dynamic genetic differentiation drives the widespread structural and functional convergent evolution of snake venom proteinaceous toxins. BMC Biol. 201, 1–31. <https://doi.org/10.1186/S12915-021-01208-9>, 2022, 20.
- Youngman, N.J., Zdenek, C.N., Dobson, J.S., Bittenbinder, M.A., Gillett, A., Hamilton, B., Dunstan, N., Allen, L., Veary, A., Veary, E., et al., 2019. Mud in the blood: novel potent anticoagulant coagulotoxicity in the venoms of the Australian elapid snake genus *Denisonia* (mud adders) and relative antivenom efficacy. Toxicol. Lett. 302, 1–6. <https://doi.org/10.1016/j.toxlet.2018.11.015>.
- Youngman, N.J., Walker, A., Naude, A., Coster, K., Sundman, E., Fry, B.G., 2020. Varespladib (LY315920) neutralises phospholipase A 2 mediated prothrombinase-inhibition induced by *Bitis* snake venoms. Comp. Biochem. Physiol., C 236. <https://doi.org/10.1016/j.cbpc.2020.108818>.
- Youngman, N.J., Lewin, M.R., Carter, R., Naude, A., Fry, B.G., 2022. Efficacy and limitations of chemically diverse small-molecule enzyme-inhibitors against the synergistic coagulotoxic activities of *Bitis* viper venoms. Molecules 27, 1–9. <https://doi.org/10.3390/MOLECULES27051733>.
- Zdenek, C.N., Hay, C., Arbuckle, K., Jackson, T.N.W., Bos, M.H.A., op den Brouw, B., Debono, J., Allen, L., Dunstan, N., Morley, T., et al., 2019a. Coagulotoxic effects by Brown snake (*Pseudonaja*) and Taipan (*Oxyuranus*) venoms, and the efficacy of a new antivenom. Toxicol. Vitro 58, 97–109. <https://doi.org/10.1016/j.tiv.2019.03.031>.
- Zdenek, C.N., op den Brouw, B., Dashevsky, D., Gloria, A., Youngman, N.J., Watson, E., Green, P., Hay, C., Dunstan, N., Allen, L., et al., 2019b. Clinical implications of convergent procoagulant toxicity and differential antivenom efficacy in Australian elapid snake venoms. Toxicol. Lett. 316, 171–182. <https://doi.org/10.1016/j.toxlet.2019.08.014>.
- Zdenek, C.N., Youngman, N.J., Hay, C., Dobson, J., Dunstan, N., Allen, L., Milanovic, L., Fry, B.G., 2020. Anticoagulant activity of black snake (Elapidae: *Pseudechis*) venoms: mechanisms, potency, and antivenom efficacy. Toxicol. Lett. 330, 176–184. <https://doi.org/10.1016/j.toxlet.2020.05.014>.